Novacyt Picks Up Bargain With Omega's Infectious Disease Unit
Clinical diagnostics firm Novacyt's M&A growth strategy is underway with the company announcing a bargain deal to buy the infectious disease business of Omega Diagnostics.
You may also be interested in...
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.
Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.